Friday, December 16, 2016

BRIEF-Alnylam Pharmaceuticals announces initial 2017 pipeline goals

* Assuming positive phase 3 data, plans to submit nda for

Patisiran at year-end 2017

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)